Clinical response and risk factors of fecal microbiota transplantation in children: a systematic review and meta-analysis

Clinical Snapshot

Key Findings

• P Value: Statistical significance mentioned for some subgroup differences

• Effect Size: Not specified in abstract

• Primary Outcome: Clinical response rates varied by condition: high efficacy demonstrated in rCDI, IBD, and ASD

• Nnt Or Sensitivity: Higher adverse event rates in IBD patients; related/friend donors improved rCDI response rates

• Confidence Interval: Not reported in abstract

Clinical Application

Limited by regulatory requirements, donor screening protocols, and specialized facility needs TGA regulation of FMT as therapeutic good; potential PBS consideration for specific indications; alignment with NHMRC guidelines for innovative therapies in children Pediatric patients with recurrent C. difficile infection, inflammatory bowel disease, and autism spectrum disorder

Abstract

UNLABELLED: The objective of this study is to investigate the clinical response and incidence of adverse events (AEs) following fecal microbiota transplantation (FMT) in children, across various diseases, populations, and treatment protocols. A systematic search was conducted across eight major Chinese and English databases, identifying 47 studies up to August 28, 2025, for inclusion. Study quality was assessed using the Quality Assessment with Diverse Studies (QuADS) tool. Single-arm rates were pooled via meta-analysis employing the Freeman-Tukey double arcsine transformation, followed by extensive subgroup comparisons to identify influencing factors. FMT demonstrated efficacy in pediatric recurrent Clostridium difficile infection (rCDI), inflammatory bowel disease (IBD), and autism spectrum disorder (ASD), although a higher incidence of AEs was observed in children with IBD. Subgroup analyses revealed that the use of donor feces from relatives or friends was associated with a higher clinical response rate in rCDI. The presence of comorbidities such as IBD diminished the response rate in rCDI patients. Younger age in rCDI and IBD patients showed a trend towards higher clinical response rates, though this did not reach statistical significance. No statistically or clinically significant differences were found in other subgroup comparisons. Meta-regression suggested IBD to be a risk factor for FMT-related AEs. CONCLUSION: This study innovatively delineates the efficacy-safety profile of pediatric FMT and outlines a pathway for optimizing individualized treatment regimens, providing crucial evidence-based guidance for clinical practice. TRIAL REGISTRATION: This study has been registered on the PROSPERO database (CRD42024614196). WHAT IS KNOWN: • Fecal Microbiota Transplantation (FMT) demonstrates preliminary therapeutic potential in several pediatric diseases. • Existing evidence remains fragmented, with limited systematic data on factors modifying efficacy and safety in children. WHAT IS NEW: • The study revealed FMT's high efficacy across rCDI, IBD, and ASD, and identified IBD as a risk factor for elevated FMT-related adverse events in pediatric patients. • Notably, related/friend donors improved rCDI response rates, while comorbidities like IBD reduced rCDI treatment efficacy.

References

1. 1.Liu, J., Sun, X., Yuan, P., Qin, Y., Wu, W., Fan, Y., Zhang, Y., Zou, L., Ren, C., & Li, S. (2026). Clinical response and risk factors of fecal microbiota transplantation in children: a systematic review and meta-analysis. European Journal of Pediatrics. https://doi.org/10.1038/s41575-021-00441-5